{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:01:42Z","timestamp":1770462102085,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The influence of continuous renal replacement therapy (CRRT) on the steady-state plasma concentration of high-dose tigecycline was investigated in septic shock patients to provide references for drug dosing.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this prospective observational study, 17 septic shock patients presenting with severe infections needing a broad-spectrum antibiotic therapy with high-dose tigecycline (100\u00a0mg per 12\u00a0h) in the intensive care unit were included and divided into CRRT group (<jats:italic>n<\/jats:italic> = 6) or non-CRRT group (<jats:italic>n<\/jats:italic> = 11). The blood samples were collected and plasma drug concentration was determined by SHIMADZU LC-20A and SHIMADZU LCMS 8040. The steady-state plasma concentration was compared between groups using unpaired <jats:italic>t<\/jats:italic>-test. Furthermore, between-groups comparisons adjusted for baseline value was also done using multivariate linear regression model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Peak concentration (C<jats:sub>max<\/jats:sub>) of tigecycline was increased in CRRT group compared to non-CRRT group, but there were no statistical differences (505.11 \u00b1 143.84 vs<jats:italic>.<\/jats:italic> 406.29 \u00b1 108.00\u00a0ng\/mL, <jats:italic>p<\/jats:italic>-value: 0.129). Trough concentration (C<jats:sub>min<\/jats:sub>) of tigecycline was significantly higher in CRRT group than in non-CRRT group, with statistical differences (287.92 \u00b1 41.91 vs<jats:italic>.<\/jats:italic> 174.79 \u00b1 33.15\u00a0ng\/mL, <jats:italic>p<\/jats:italic>-value: 0.000, adjusted <jats:italic>p<\/jats:italic>-value: 0.000). In safety, C<jats:sub>min<\/jats:sub> was reported to be a useful predictor of hepatotoxicity with a cut-off of 474.8\u00a0ng\/mL. In our studies, C<jats:sub>min<\/jats:sub> of all patients in CRRT group was lower than 474.8\u00a0ng\/mL.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The plasma concentration of tigecycline was increased in septic shock patients with CRRT treatment and only C<jats:sub>min<\/jats:sub> shown statistical differences. No dose adjustment seems needed in the view of hepatotoxicity.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/www.chictr.org.cn\/<\/jats:ext-link>, identifier ChiCTR2000037475.<\/jats:p>","DOI":"10.3389\/fphar.2023.1118788","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T09:10:17Z","timestamp":1678439417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of continuous renal replacement therapy on the plasma concentration of tigecycline in patients with septic shock: A prospective observational study"],"prefix":"10.3389","volume":"14","author":[{"given":"Fang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Tian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shuang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Gang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2049936120952605","DOI":"10.1177\/2049936120952605","article-title":"Cutaneous hyperpigmentation secondary to high-dose tigecycline: A case report","volume":"7","author":"Alsemari","year":"2020","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00134-017-4755-7","article-title":"Acute kidney injury in sepsis","volume":"43","author":"Bellomo","year":"2017","journal-title":"Intensive Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.bpa.2017.08.005","article-title":"Renal replacement therapy and anticoagulation","volume":"31","author":"Brandenburger","year":"2017","journal-title":"Best. Pract. Res. Clin. Anaesthesiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13054-018-2278-4","article-title":"Tigecycline in critically ill patients on continuous renal replacement therapy: A population pharmacokinetic study","volume":"22","author":"Broeker","year":"2018","journal-title":"Crit. Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-018-5134-8","article-title":"Unexplained mortality differences between septic shock trials: A systematic analysis of population characteristics and control-group mortality rates","volume":"44","author":"de Grooth","year":"2018","journal-title":"Intensive Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit. care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.xphs.2017.09.006","article-title":"Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration","volume":"107","author":"Dorn","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2011.02.004","article-title":"Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009","volume":"37","author":"Dowzicky","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/ftd.0000000000000784","article-title":"Safety and efficacy of tigecycline in intensive care unit patients based on therapeutic drug monitoring","volume":"42","author":"Fan","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4067\/s0034-98872022000300283","article-title":"Efectividad de anticoagulaci\u00f3n regional con citrato en terapia de reemplazo renal continua","volume":"150","author":"Fr\u00edas","year":"2022","journal-title":"Rev. Med. Chil."},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/cc13942","article-title":"High dose of tigecycline for extremely resistant gram-negative pneumonia: Yes, we can","volume":"18","author":"Garnacho-Montero","year":"2014","journal-title":"Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Med. Baltim."},{"key":"B13","volume-title":"The Sanford guide to antimicrobial therapy","author":"Gilbert","year":"2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijantimicag.2010.04.009","article-title":"In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii","volume":"36","author":"Hawser","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1308\/rcsann.2016.0126","article-title":"Patient and disease factors predictive of adverse perioperative outcomes after nephrectomy","volume":"98","author":"Henderson","year":"2016","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13613-020-00758-5","article-title":"High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: Do we need even higher doses in patients under CRRT?","volume":"10","author":"Honore","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jama.2017.0131","article-title":"Management of sepsis and septic shock","volume":"317","author":"Howell","year":"2017","journal-title":"Jama"},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1099\/jmm.0.036483-0","article-title":"Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China","volume":"61","author":"Hu","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/0091270011416938","article-title":"Tigecycline pharmacokinetics in subjects with various degrees of renal function","volume":"52","author":"Korth-Bradley","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3389\/fphar.2020.00786","article-title":"Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1086\/379825","article-title":"Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial","volume":"38","author":"MacArthur","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed?","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10047-019-01139-x","article-title":"Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: In vitro studies","volume":"23","author":"Onichimowski","year":"2020","journal-title":"J. Artif. Organs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/jac\/dki248","volume":"56","author":"Pankey","year":"2005","journal-title":"Tigecycline. J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1128\/jcm.01802-09","article-title":"Heteroresistance to teicoplanin in Enterococcus faecium harboring the vanA gene","volume":"47","author":"Qu","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13054-022-04098-7","article-title":"Right dose, right now: Bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial","volume":"26","author":"Roggeveen","year":"2022","journal-title":"Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"Jama"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijid.2019.03.011","article-title":"Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit","volume":"82","author":"Xu","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: A systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.5414\/cp203669","article-title":"PK\/PD study of tigecycline in severely infected patients with continuous renal replacement therapy","volume":"58","author":"Zhao","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S365512","article-title":"Population pharmacokinetics of tigecycline: A systematic review","volume":"16","author":"Zhou","year":"2022","journal-title":"Drug Des. Devel Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1118788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T09:10:22Z","timestamp":1678439422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1118788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":31,"alternative-id":["10.3389\/fphar.2023.1118788"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1118788","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1118788"}}